GENALICE RELEASES ITS BREAKTHROUGH DNA DATA ANALYSIS SOLUTION GENALICE MAP ON AMAZON

HARDERWIJK, the Netherlands – Today, biomedical big data solutions company GENALICE announced that they have added a cloud solution via Amazon Web Services (AWS) to its on-premise solution, the GENALICE VAULT.  Both are deployment options of GENALICE MAP, the company’s breakthrough Next-Generation Sequencing (NGS) data processing software. GENALICE MAP processes genomics data up to 100-fold faster than conventional tools and produces improved quality outcome data, while radically reducing the storage requirements. It is the only product in the market today that makes secondary analysis of large-scale genomics data truly effective and affordable.

GENALICE’s CEO Hans Karten commented: “More and more genomics data is being stored in the cloud. To facilitate companies and institutes adopting cloud storage, we have developed an AWS implementation of our product. The beauty of a pure software solution is the opportunity to install it in every hardware environment with the right specifications. It appeared that both Amazon and Google make use of the same commodity servers as we do for our on-premise solution. This made it relatively simply to add this AWS highly scalable cloud solution to our deployment options.”

Jos Lunenberg, GENALICE’s Chief Business Officer, added: “We are new kid on the block with unprecedented specifications on speed, quality and cost-effectiveness. For many, this is still hard to belief. Therefore, we have offered potential customers the opportunity to test drive our on-premise solution. With the launch of our AWS solution, this can be done with much less effort: register via our website, sign the validation agreement and start testing. For the first 25 centers who sign up we will provide a full month of unlimited testing.”

About GENALICE

GENALICE is a highly innovative biomedical big data solutions company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, it has introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome, exome and transcriptome sequencing for biomarker discovery and clinical application.
More information on GENALICE can be found at www.genalice.com.